Dr. Peter Black Explains Bladder-Sparing Strategies for High-Grade NMIBC (video)
Date Posted
Image
Dr. Peter Black outlines bladder-preservation strategies in high-grade non-muscle invasive bladder cancer, covering first-line optimization through second-line options.
In the BCG-naive space, the BRIDGE trial comparing gemcitabine/docetaxel to BCG has completed accrual, and the BCG plus N803 interleukin-15 superagonist combination showed 100% complete response in the first nine patients of a phase 1b study. The CISTO trial, a pragmatic study of 570 patients choosing between bladder preservation and radical cystectomy, found physical function equivalent between groups by nine months and better emotional function and generic health-related quality of life in the cystectomy arm.